TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22315495

Group type: EXPERIMENTAL
Intervention: 400 mg/day imatinib
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 800 mg/day imatinib
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Imatinib C(min) > 1165 ng/mL on Day 29
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Imatinib C(min) levels
Number of subjects: 100
Study: 19821004

Group type: EXPERIMENTAL
Intervention: 5% ethanolamine oleate after gelatin sponge administration (group E)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Fibrin glue and iodized oil (group F)
Number of subjects: 82
Study: 17585023

Group type: EXPERIMENTAL
Intervention: P125 (1.00 g protein x kg(‐1) x d(‐1))
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: P94 (0.75 g protein x kg(‐1) x d(‐1))
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: P63 (0.50 g protein x kg(‐1) x d(‐1))
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Males (independent of protein intake)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Age and dietary protein effect on serum albumin concentrations
Number of subjects: 36
Study: 16128940

Group type: EXPERIMENTAL
Intervention: Walking exercise (G1)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Nonexercise (G2)
Number of subjects: 383
Study: 14566492

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia (5-10 mg.kg(‐1).h(‐1))
Number of subjects: 36

Group type: COMPARATOR
Intervention: Isoflurane anesthesia (0.5%-1.0%)
Number of subjects: 36
Study: 10458256

Group type: EXPERIMENTAL
Intervention: Enhanced compassion videotape
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard videotape
Number of subjects: 210
Study: 7790243

Group type: EXPERIMENTAL
Intervention: AHFX‐S: 1.6 Gy/fraction, twice daily (6‐h interval), 5 days/week, total dose of 67.2 Gy/42 fractions/6 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: AFX‐C: 1.8 Gy/fraction/day, 5 daily fractions/week to 54 Gy/30 fractions/6 weeks, total dose of 70.5 Gy/41 fractions/6 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 75
Study: 2154086

Group type: EXPERIMENTAL
Intervention: Lisinopril plus sodium restriction (low salt group)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lisinopril plus hydrochlorothiazide (diuretic group)
Number of subjects: 25
Study: 7272394

Group type: EXPERIMENTAL
Intervention: Focused attention on one channel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divided attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High stimulation rate and/or difficult targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow negative shift (SNS)
Number of subjects: 0
Study: 31582554

Group type: EXPERIMENTAL
Intervention: Homozygous carriers of the fibrinogen gamma gene (FGG) rs2066865
Number of subjects: 4374

Group type: EXPERIMENTAL
Intervention: Cancer patients homozygous for the FGG variant
Number of subjects: 4374

Group type: EXPERIMENTAL
Intervention: Cancer patients homozygous carriers of FGG
Number of subjects: 4374

Group type: COMPARATOR
Intervention: Cancer patients without risk alleles
Number of subjects: 4374

Group type: EXPERIMENTAL
Intervention: Synergistic effect of rs2066865 and active cancer
Number of subjects: 4374
Study: 31385737

Group type: EXPERIMENTAL
Intervention: Integrated Psychological Therapy (IPT) for Treatment-Resistant Schizophrenia (TRS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Integrated Psychological Therapy (IPT) for Nontreatment Resistant Schizophrenia (NTRS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) for Nontreatment Resistant Schizophrenia (NTRS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) for Treatment-Resistant Schizophrenia (TRS)
Number of subjects: 48
Study: 27465911

Group type: EXPERIMENTAL
Intervention: 15 g soy protein with 66 mg isoflavone (SPI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 15 g soy protein alone (SP)
Number of subjects: 200
Study: 26088581

Group type: EXPERIMENTAL
Intervention: Weight management program intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Wait-listed group (Control)
Number of subjects: 140
Study: 23651878

Group type: COMPARATOR
Intervention: Placebo (positive expectation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nocebo (negative expectation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neutral (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MedON (with antiparkinsonian medication)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MedOFF (without antiparkinsonian medication)
Number of subjects: 24
Study: 21824940

Group type: EXPERIMENTAL
Intervention: Phlebotomy (diagnostic blood loss)
Number of subjects: 17676
Study: 20031889

Group type: EXPERIMENTAL
Intervention: Experimental group received education and counseling about ACS symptoms and actions required
Number of subjects: 3522

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 3522

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3522
Study: 16533495

Group type: EXPERIMENTAL
Intervention: Systematic approach to study tactile sense regarding surface roughness
Number of subjects: 0
Study: 15471991

Group type: EXPERIMENTAL
Intervention: 81 mg daily dose of aspirin
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 325 mg daily dose of aspirin
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 650 mg daily dose of aspirin
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: All three aspirin doses
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 11697842

Group type: EXPERIMENTAL
Intervention: E7070 at 200 mg/m2/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: E7070 at 160 mg/m2/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: E7070 at 130 mg/m2/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: E7070 (various doses)
Number of subjects: 33
Study: 9593027

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg twice daily for 3 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg twice daily for 12 months)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study: 7930727

Group type: EXPERIMENTAL
Intervention: Fc gamma RIIa‐H/H131 phenotype
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Immunization with pneumococcal vaccine
Number of subjects: 48
Study: 3294594

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg three times a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg three times a day) + Nifedipine (20 mg tablet twice a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg tablet twice a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg tablet twice a day) + Captopril (25 mg three times a day)
Number of subjects: 0
Study: 30354904

Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) CRP testing
Number of subjects: 2844

Group type: EXPERIMENTAL
Intervention: Normal CRP levels
Number of subjects: 2844

Group type: EXPERIMENTAL
Intervention: Elevated CRP levels
Number of subjects: 2844
Study: 27366817

Group type: EXPERIMENTAL
Intervention: Single-step advancement with FMA
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Stepwise advancement with FMA
Number of subjects: 34
Study: 26616119

Group type: EXPERIMENTAL
Intervention: Training in use of the taxonomy (1‐day workshops and distance group tutorials)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: BCTTv1 (Behaviour Change Technique Taxonomy version 1)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Training methods
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: BCTTv1 for reporting descriptions of observed interventions
Number of subjects: 400
Study: 24511883

Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (no financial rewards)
Number of subjects: 140
Study: 20513050

Group type: EXPERIMENTAL
Intervention: Triamcinolone-impregnated bioresorbable dressing (Nasopore)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline-impregnated dressing
Number of subjects: 19
Study: 17889863

Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (aspirin)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 10
Study: 15673801

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 180
Study: 12548189

Group type: EXPERIMENTAL
Intervention: Hysteroscopic endometrial resection
Number of subjects: 181

Group type: COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy
Number of subjects: 181

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 181
Study: 10389557

Group type: EXPERIMENTAL
Intervention: Subcutaneous lignocaine
Number of subjects: 166

Group type: COMPARATOR
Intervention: No local anaesthetic (Control)
Number of subjects: 166
Study: 8550787

Group type: EXPERIMENTAL
Intervention: recombinant human GH (0.02 mg/kg BW.day, sc)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study: 1990744

Group type: EXPERIMENTAL
Intervention: Emergency PTCA
Number of subjects: 89

Group type: COMPARATOR
Intervention: Delayed PTCA (18 to 48 hours)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Ineffective reperfusion (greater than 90% stenosis)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Residual lumen less than 0.4 mm after thrombolysis
Number of subjects: 89

Group type: COMPARATOR
Intervention: Greater than 90% stenosis
Number of subjects: 89
Study: 6308965

Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Combination of ampicillin, methicillin, and netilmicin (AMN)
Number of subjects: 58
Study: 30773174

Group type: EXPERIMENTAL
Intervention: Flank/abdominal radiotherapy
Number of subjects: 149

Group type: COMPARATOR
Intervention: No flank/abdominal radiotherapy
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: One reason to be stage III
Number of subjects: 149

Group type: COMPARATOR
Intervention: Two or three reasons to be stage III
Number of subjects: 149
Study: 28731928

Group type: EXPERIMENTAL
Intervention: Serious game (Staying Alive)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Online course (PowerPoint lecture)
Number of subjects: 82
Study: 25846344

Group type: EXPERIMENTAL
Intervention: Celecoxib 6 mg·kg(‐1) preoperatively, followed by 3 mg·kg(‐1) twice daily for five doses
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 23078753

Group type: EXPERIMENTAL
Intervention: Maxillary sinus lifting with autogenous bone augmentation and implant insertion at 6 months post grafting (Group I)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Maxillary sinus lifting with autogenous bone augmentation mixed with PRP (Group II)
Number of subjects: 15
Study: 22048171

Group type: EXPERIMENTAL
Intervention: 2 doses of 20/20F at Months 0,6 (n=240)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: 2 doses of 40/40F at Months 0,6 (n=241)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: 2 doses of 40/40F at Months 0,2 (n=240)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: 3 doses of 20/20F at Months 0,1,6 (licensed schedule, n=239)
Number of subjects: 1000
Study: 19537094

Group type: EXPERIMENTAL
Intervention: Panavir (monotherapy for chronic TBE; n = 30)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Panavir (combined therapy for acute TBE; n = 113)
Number of subjects: 143
Study: 17854480

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Usual General Practitioner (GP) care
Number of subjects: 143
Study: 15219658

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study: 11478545

Group type: EXPERIMENTAL
Intervention: Patient Decision Group (n = 41)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Surgeon Decision Group (n = 39)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Advised to undergo mastectomy (n = 34)
Number of subjects: 114
Study: 9553318

Group type: EXPERIMENTAL
Intervention: Pregnant women with PGDM
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Pregnant women with GDM
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Cord blood of fetuses from PGDM and GDM mothers
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group (non-diabetic pregnant women)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: All study groups
Number of subjects: 251
Study: 7996212

Group type: EXPERIMENTAL
Intervention: Videotaped vignette with PPE
Number of subjects: 62

Group type: COMPARATOR
Intervention: Videotaped vignette without PPE (Control)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (PPE and NO PPE)
Number of subjects: 62
Study: 3052153

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 0
Study: 31702625

Group type: EXPERIMENTAL
Intervention: Experienced assistant group
Number of subjects: 331

Group type: COMPARATOR
Intervention: Inexperienced assistant group
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 331
Study: 28245914

Group type: EXPERIMENTAL
Intervention: Vacuum dressing
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard dressing (Control)
Number of subjects: 90
Study: 25845448

Group type: EXPERIMENTAL
Intervention: Andolast 2 mg t.i.d.
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Andolast 4 mg t.i.d.
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Andolast 8 mg t.i.d.
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study: 24579282

Group type: EXPERIMENTAL
Intervention: WITAUL distraction technique
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control method (deep breathing)
Number of subjects: 160
Study: 21451140

Group type: EXPERIMENTAL
Intervention: α(1)-blocker (prazosin, 1 mg/20 kg body mass)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: α(1)-blocker (prazosin)
Number of subjects: 12
Study: 18458361

Group type: EXPERIMENTAL
Intervention: Sports beans
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sports drink
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gel
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water
Number of subjects: 16
Study: 16475496

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream
Number of subjects: 74

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 74
Study: 12656931

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10638377

Group type: EXPERIMENTAL
Intervention: High carbohydrate (CHO) diet for 2 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low carbohydrate (CHO) diet for 2 days
Number of subjects: 8
Study: 8746332

Group type: EXPERIMENTAL
Intervention: Sterol-enriched fraction from canola oil
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Canola oil
Number of subjects: 21

Group type: COMPARATOR
Intervention: Water
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Other lipids tested (petrolatum, fish oil, borage oil, sunflower seed oil, shea butter, fractions of unsaponifiable lipids from canola oil and shea butter)
Number of subjects: 21
Study: 1539466

Group type: EXPERIMENTAL
Intervention: Recombinant B subunit-whole cell cholera vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Old type B subunit-whole cell cholera vaccine
Number of subjects: 0
Study: 3886392

Group type: EXPERIMENTAL
Intervention: CHOP regimen (cyclophosphamide, adriamycin, vincristine and prednisone)
Number of subjects: 141

Group type: COMPARATOR
Intervention: MEV regimen (methotrexate, cyclophosphamide and vincristine)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: CHOP regimen
Number of subjects: 141

Group type: COMPARATOR
Intervention: MEV regimen
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 141
Study: 31789482

Group type: EXPERIMENTAL
Intervention: 25-hydroxy vitamin D (25(OH)D) levels in the lowest tertile (<11 ng/mL)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: FGF-23 levels in the highest tertile (>3750 RU/mL)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Higher PTH levels
Number of subjects: 219
Study: 30593883

Group type: EXPERIMENTAL
Intervention: Phenotype-stratified clinical trial (Steroids in Eosinophil Negative Asthma - SIENA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-specified contingency plans
Number of subjects: 0
Study: 27937046

Group type: EXPERIMENTAL
Intervention: Trigger point dry needling in addition to personalized, evidence-based physical therapy treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Personalized, evidence-based physical therapy treatment
Number of subjects: 120
Study: 24929431

Group type: EXPERIMENTAL
Intervention: Liraglutide (GLP-1 receptor agonist)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glimepiride (sulfonylurea)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (tablets)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (injections)
Number of subjects: 16
Study: 22492085

Group type: EXPERIMENTAL
Intervention: Varenicline 2 mg/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bupropion 300 mg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nicotine deprivation (1, 6, and 18 hr)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Monetary reinforcement
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Craving, mood, withdrawal, and subjective cigarette effects
Number of subjects: 62
Study: 19947274

Group type: EXPERIMENTAL
Intervention: Digital acupoint pressure (DAP group)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Chinese herb medicine of Gentongping (medicine group)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both groups (DAP and medicine)
Number of subjects: 400
Study: 17434847

Group type: EXPERIMENTAL
Intervention: Enfuvirtide-based therapy
Number of subjects: 64
Study: 15309728

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy combined with hyperthermia or activated carbon particles
Number of subjects: 1161
Study: 12002878

Group type: EXPERIMENTAL
Intervention: Unilateral injections of botulinum toxin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Bilateral injections of botulinum toxin
Number of subjects: 49
Study: 9828734

Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler (MDI)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Jet Nebuliser
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrasonic Nebuliser
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrasonic Nebuliser and MDI
Number of subjects: 20
Study: 8011011

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Analgesic medications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2735497

Group type: EXPERIMENTAL
Intervention: Neurotropin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 0
Study: 812894

Group type: EXPERIMENTAL
Intervention: IgG fractions purified by ion exchange chromatography and specific immunosorbents
Number of subjects: 0

Group type: COMPARATOR
Intervention: IgE fractions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cromolyn sodium
Number of subjects: 0
Study: 31369394

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 70

Group type: COMPARATOR
Intervention: Both groups (Caffeinated and Decaffeinated coffee)
Number of subjects: 70
Study: 28408243

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg per day and bevacizumab 15 mg/kg every 21 days
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Erlotinib and bevacizumab in T790M-positive patients
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Erlotinib and bevacizumab in T790M-negative patients
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Safety analysis of erlotinib and bevacizumab
Number of subjects: 109
Study: 25449864

Group type: EXPERIMENTAL
Intervention: Active rTMS applied to the left DLPFC (n=78)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Sham rTMS (n=39)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 117
Study: 23497601

Group type: EXPERIMENTAL
Intervention: CTC (with reduced cathartic preparation and standard bowel preparation)
Number of subjects: 14000

Group type: COMPARATOR
Intervention: FOBT (biannual for three rounds)
Number of subjects: 14000

Group type: EXPERIMENTAL
Intervention: OC
Number of subjects: 14000
Study: 21473962

Group type: EXPERIMENTAL
Intervention: Prasugrel pretreatment (30 mg after diagnosis + 30 mg at PCI)
Number of subjects: 4100

Group type: COMPARATOR
Intervention: Prasugrel non-pretreatment (60 mg at PCI)
Number of subjects: 4100

Group type: EXPERIMENTAL
Intervention: Prasugrel (5 or 10 mg daily)
Number of subjects: 4100
Study: 19551471

Group type: EXPERIMENTAL
Intervention: Nurse-CHW team
Number of subjects: 613

Group type: COMPARATOR
Intervention: Usual CC
Number of subjects: 613
Study: 17027548

Group type: EXPERIMENTAL
Intervention: Concave insert with retention of the posterior cruciate ligament
Number of subjects: 64

Group type: COMPARATOR
Intervention: Posterior-stabilized insert with resection of the posterior cruciate ligament
Number of subjects: 64

Group type: COMPARATOR
Intervention: Flat insert
Number of subjects: 64

Group type: COMPARATOR
Intervention: Concave insert
Number of subjects: 64
Study: 15472839

Group type: EXPERIMENTAL
Intervention: PCV7 followed by PPSV23
Number of subjects: 383

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: PCV7 followed by PPSV23 in children aged 1-2 years
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: PCV7 followed by PPSV23 in older children
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Polysaccharide booster vaccination
Number of subjects: 383